Cancer vaccine development

Expert Opinion on Investigational Drugs

Volumn 7, Issue 9, 1998, Pages 1439-1452

  Schlom, J ^a   Tsang, K Y ^a   Kantor, J A ^a   Abrams, S I ^a   Zaremba, S ^a   Greiner, J ^a   Hodge, J W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Agonist epitopes; ALVAC; Cancer vaccines; Carcinoembryonic antigen; Cytokines; Cytotoxic T lymphocyte (CTL); Immunotherapy; MUC 1; Peptides; Prostate specific antigen; Ras oncogene; T cell costimulation; Vaccines; Vaccinia

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; PLASMID VECTOR; PROSTATE SPECIFIC ANTIGEN; RAS PROTEIN; RECOMBINANT VACCINE; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL MODEL; ANTIGEN PRESENTATION; CANCER THERAPY; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; EXPRESSION VECTOR; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR CLONING; NONHUMAN; ONCOGENE RAS; RECOMBINANT DNA TECHNOLOGY; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0031705714     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.7.9.1439     Document Type: Review

References (104)